PLK1和P53蛋白在卵巢上皮性癌中的表达及其意义

目的检测POLO样蛋白激酶1(PLK1)和P53蛋白在卵巢上皮性癌中的表达,探讨其与患者预后的关系。方法采用免疫组织化学SP法检测20例正常卵巢组织、19例卵巢良性上皮性肿瘤组织和52例卵巢上皮性癌组织中PLK1和P53蛋白的表达情况,分析其与卵巢癌临床病理指标的关系及二者在卵巢癌组织中表达的相关性,单因素和多因素Logistic回归分析影响卵巢癌患者预后的危险因素,Kaplan-Meier法分析PLK1和P53表达与卵巢癌患者预后的关系。结果 PLK1和P53在卵巢上皮性癌组织中的表达分别为38.5%和67.3%,显著高于良性肿瘤和正常卵巢组织(P<0.05)。在卵巢上皮性癌中,PLK1和P53异常高表达与临床分期和组织分化相关,临床分期越晚、组织分化越差的癌组织中PLK1和P53蛋白表达越高(P<0.05);PLK1蛋白的表达与P53蛋白的表达呈负相关(r=-0.629,P=0.000)。单因素Logistic回归分析显示PLK1、P53、临床分期、组织分化和淋巴结转移是影响卵巢癌患者预后的因素,多因素Logistic回归分析显示仅PLK1是影响卵巢癌患者预后的独立因素(OR=2.288,P=0.025,95%CI:0.105⁵0.050)。与其他患者相比,PLK1表达阳性同时P53表达阳性的卵巢癌患者,生存期最短(?2=17.246,P=0.037)。结论 PLK1和P53共同参与了卵巢癌的发生发展,PLK1可作为判断卵巢癌患者预后的标志物。

Expression and significance of PLK1 and P53 in epithelial ovarian cancer

Objective To detect the expression of PLK1 and P53 proteins in epithelial ovarian cancer, investigate their relationships with the progression of ovarian cancer. Methods The expression of PLK1 and P53 in 20 specimens of normal ovarian tissues, 19 specimens of benign epithelial ovarian tumor and 52 specimens of epithelial ovarian cancer was detected by immunohistochemistry SP method. Their correlations to the clinicopathologic characteristics of epithelial ovarian cancer and their interrelationships were analyzed. Risk factors of progression were discussed by Univariate and multivariate Logistic regression analysis, the relations between PLK1 and P53 expression and the prognosis were measured by Kaplan-Meier analysis. Results The positive rates of PLK1 and P53 proteins in epithelial ovarian cancer were 38.5% and 67.3%, significant differences were noted between epithelial ovarian cancer and normal ovarian tissues, benign ovarian tumors （P〈0.05）. In epithelial ovarian cancer, up-regulation of PLK1 and P53 were associated with advanced FIGO stage and poor differentiation （P〈0.05）. PLK1 expression was negatively correlated to P53 expression （r =-0.629, P=0.000）. PLK1, P53, FIGO stage, differentiation, and lymph nodes metastasis were all risk factors of progression for ovarian cancer patients showed by univariate Logistic regression analysis, but only PLK1was the independent factors of progression measured by multivariate Logistic regression analysis （OR=2.288, P=0.025, 95% CI： 0.105-50.050）. Compared to other patients, the survival time of patients with PLK1 and P53 positive expression was obviously shorter （χ2=17.246, P=0.037）. Conclusion PLK1 and P53 protein are implicated in the development of epithelial＆amp;nbsp;ovarian cancer, PLK1 may be a potential biomarker of progression for ovarian cancer.